HLVX HilleVax Inc.

FDA Catalyst Company
10.17
-1.12  -10%
Previous Close 11.29
Open 10.53
52 Week Low 9.84
52 Week High 20.95
Market Cap $339,954,716
Shares 33,427,209
Float 17,313,583
Enterprise Value $373,849,715
Volume 156,155
Av. Daily Volume 100,420
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Latest News

  1. BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the closing of its initial public offering of 13,529,750 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,764,750 additional shares, at an initial public offering price of $17.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $230.0 million. HilleVax's common stock is listed on the Nasdaq Global Select Market under the ticker symbol "HLVX."

    J.P. Morgan, SVB Securities, Stifel and…

    View Full Article
  2. BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, reported today dosing of the first subjects in its previously announced Phase 2b clinical trial of HIL-214, the company's virus-like particle (VLP) based vaccine candidate, for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection in infants.

    "We're pleased to have dosed the first subjects in this Phase 2b study, the first ever field efficacy clinical trial of a norovirus vaccine candidate in infants," said Rob Hershberg, MD, PhD, Chairman and Chief Executive Officer of HilleVax. "We believe HIL-214 has the potential to address…

    View Full Article
View All HilleVax Inc. News